Record Details

Valutazione dei costi di trattamento dei disturbi psicotici con olanzapina, risperidone e neurolettici tipici di un DSM italiano

Farmeconomia. Health Economics and Therapeutic Pathways

View Archive Info
 
 
Field Value
 
Title Valutazione dei costi di trattamento dei disturbi psicotici con olanzapina, risperidone e neurolettici tipici di un DSM italiano
 
Creator Rossi, I.
Guidi, L.
 
Subject Pharmacoeconomics; Health economics
 
Description Objective of the present retrospective analysis was to evaluate resources consumption for psychotic patients treatment with olanzapine (OLZ), risperidone (RIS) or typical neuroleptics (NL) during year 2000 in the Dipartimento di Salute Mentale (DSM) of Ravenna. The screening of total number of psychotic patients followed in the Ravenna DSM during year 2000 generated 26 cases treated with OLZ, 22 treated with RIS and 17 treated with NL that were respecting criteria of equivalence for age and illness severity. For these patients we analyzed pharmacological, non pharmacological (medical visits, nurse visits, social assistance, rehabilitative sessions) and hospital interventions during the year of observation, choosing the point of view of the DSM for costs attribution. The analysis of pharmacological interventions evidentiated a major usage of associated neuroleptics in the RIS and NL groups in respect to OLZ (p
 
Publisher SEEd Medical Publishers
 
Date 2001-12-15
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
—
 
Format application/pdf
 
Identifier https://journals.seedmedicalpublishers.com/index.php/FE/article/view/734
10.7175/fe.v2i4.734
 
Source Farmeconomia. Health economics and therapeutic pathways; Vol 2, No 4 (2001); 217-222
2240-256X
 
Language eng
 
Relation https://journals.seedmedicalpublishers.com/index.php/FE/article/view/734/838
 
Rights Copyright (c) 2001 Farmeconomia. Health economics and therapeutic pathways
http://creativecommons.org/licenses/by-nc/4.0